RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
  Adrenergics
  Analgesics
  Anti Cancer Drugs
   Rituximab
   Tarvacin
  Anti-Clotting Drugs
  Anti-Inflammatory
  Antibiotics
  Anticholesterol
  Antihypertensives
  Antivirals
  Fatty Acids
  Hypnotics
  Metals
  PPI
  Surfactants
  Varenicline
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Rituximab Channel

subscribe to Rituximab newsletter
Latest Research : Pharmacology : Anti Cancer Drugs : Rituximab

   EMAIL   |   PRINT
Rituximab may also benefit people with lupus

Jun 9, 2005 - 1:26:00 PM , Reviewed by: Rashmi Yadav
There was a significant improvement in 16 of the patients and four others were stabilized. Brain scans demonstrated that the adverse changes that occurred with the disease improved.

 
[RxPG] A drug used to treat cancer may also benefit people with lupus who have complications of the central nervous system. Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy.

Lupus is a disorder of the immune system in which the body attacks itself, causing pain, inflammation and diffuse damage to many organs. In a significant number of cases, the central nervous system is effected which can lead to psychiatric and neurological disturbances. This form of lupus dramatically reduces the quality of life for patients, more so than other manifestations of the disease in which, for example, the kidneys might be affected.

Clinical professor Michael Neuwelt, at the University of Californian San Francisco and Stanford University, presented results of a trial involving 22 patients over 16 months. "I spent considerable time with oncologists and saw how the drug works in patients with non-Hodgkins lymphoma. Patients with blood disorders of lupus and severe complications of the central nervous system (CNS) also surprisingly improved," he said.

Over half of the patients received rituximab on its own, others received it in combination with steroids, and one-third with the current standard treatment of severe CNS lupus with chemotherapy, cyclophosphamide, combined with rituximab. Rituximab targets a specific type of white blood cells (B cells which make auto-antibodies) and uniquely removes those early B cells before they become harmful. "Rituximab appears to be quite effective. It is a kinder, gentler form of treatment lasting up to six months with a low risk of side-effects, compared to previous treatments of high-dose steroids, and chemo-therapy," said Professor Neuwelt.

There was a significant improvement in 16 of the patients and four others were stabilized. Brain scans demonstrated that the adverse changes that occurred with the disease improved.

Professor Neuwelt specialises in diagnosing and treating patients with CNS lupus. "It can be difficult to disentangle psychiatric disorders that arise from other causes," he states. In a portion of patients, depression, seizures, verbal comprehension, perception and memory will be associated with lupus. People are understandably afraid to admit that their IQ has gone down or that they cannot read any more in fear of losing their job," he continued. A careful history, ruling out other causes such as infection and drug side effects has improved diagnostic accuracy.

Professor Neuwelt, like others using this well-tested oncological drug in other forms of lupus, is concerned about the depletion of the B cells by rituximab for the long term. However, the risk/benefit ratio from this new treatment in its early stages is extremely promising. "It is the first drug in my 26 years of treating patients with severe central nervous system lupus, used alone or in combination with other therapies that has not only significantly boosted the quality of life for patients with this dreadful disease, but also reduced the burden of side effects of standard treatment with steroids and cyclophosphamide. However, we desperately need randomized-controlled trials." he concluded.



Publication: Annual European Congress of Rheumatology, EULAR 2005, in Vienna
On the web: www.eshre.com 

Advertise in this space for $10 per month. Contact us today.


Related Rituximab News
Rituximab effective in treating chronic graft-versus-host disease
Rituximab maintenance therapy dramatically improves survival in lymphoma
Rituximab to be Considered for Front-Line Treatment of Intermediate Grade or Aggressive CD-20-positive, B-cell, non-Hodgkin's lymphoma
Rituximab may also benefit people with lupus
DANCER Study shows RA drug rituximab is safe and well-tolerated

Subscribe to Rituximab Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)